Association of Androgen Receptor, Prostate-Specific Antigen, and CYP19 Gene Polymorphisms with Prostate Carcinoma and Benign Prostatic Hyperplasia in a North Indian Population

被引:13
|
作者
Soni, Abha [1 ]
Bansal, Anju [1 ]
Mishra, Ashwani Kumar [1 ]
Batra, Jyotsna [2 ,3 ]
Singh, Laishram Chandreshwor [1 ]
Chakraborty, Anurupa [1 ]
Yadav, Dhirendra Singh [1 ]
Mohanty, Nayan K. [4 ,5 ]
Saxena, Sunita [1 ]
机构
[1] Natl Inst Pathol ICMR, New Delhi 110029, India
[2] Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Brisbane, Qld 4001, Australia
[3] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia
[4] Safdarjang Hosp, Dept Urol, New Delhi, India
[5] Vardhman Mahavir Med Coll, New Delhi, India
基金
澳大利亚国家健康与医学研究理事会;
关键词
CAG REPEAT LENGTH; CANCER; RISK; AROMATASE; PSA; IDENTIFICATION; EXPRESSION; IMPACT; GGN;
D O I
10.1089/gtmb.2011.0322
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The genes involved in androgen pathway and metabolism have been reported to contribute considerably to prostate carcinoma (CaP) risk. The present study investigated the association of androgen receptor (AR), prostate-specific antigen (PSA or KLK3), and cytochrome P450 (CYP19) gene polymorphisms in CaP (n = 105) and benign prostatic hyperplasia (BPH) (n = 120) in comparison to normal healthy controls (n = 106) in an Indian population. We also evaluated the functional consequences of these gene variants on AR and PSA mRNA expression. Significant association of short AR CAG repeats (<= 24) with risk of CaP (odds ratios [OR] = 2.98, p < 0.001) and BPH (OR = 1.96, p = 0.01) was observed; however, CYP19 gene polymorphism was not found to be associated with disease phenotype (p > 0.05). PSA G-158A SNP was found to be significantly associated with risk of CaP (AA: OR = 2.68, p = 0.016 and GA: OR = 2.07, p = 0.018) p-trend 0.031 and BPH (AA: OR = 3.46, p < 0.001 and GA: OR = 2.47, p = 0.03) p-trend 0.009, respectively. PSA G-158A genotype independently increased the risk of developing BPH (OR = 16.37, p < 0.001), irrespective of AR CAG repeat length. Using quantitative real-time polymerase chain reaction, we found a significant upregulation of AR and PSA mRNA expression in CaP comparison to BPH. While short AR CAG (<= 24) repeats were associated with higher AR mRNA expression in CaP (p = 0.002), the PSA SNP did not correlate with its mRNA expression. Interestingly, significantly higher risk estimates for CaP were observed for the combined analysis of short AR CAG and CYP19 genotypes (A2A2) (OR = 7.18, p < 0.001) or A2A3 (OR = 7.60, p = 0.004). Our results suggest significant association of androgen signaling gene polymorphisms with risk of CaP and BPH and provide evidence for a putative functional role of AR CAG repeat in regulating its mRNA expression and warrant the need of larger studies in the Indian population to confirm our results.
引用
收藏
页码:835 / 840
页数:6
相关论文
共 50 条
  • [1] Benign prostatic hyperplasia and prostate-specific antigen
    Pejcic, Tomislav
    Acimovic, Miodrag
    Dzamic, Zoran
    Radovanovic, Milan
    Hadzi-Djokic, Jovan
    VOJNOSANITETSKI PREGLED, 2015, 72 (05) : 447 - 453
  • [2] PROSTATE-SPECIFIC ANTIGEN IN THE EXPRESSED PROSTATIC FLUID OF MEN WITH BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CARCINOMA
    KIM, ED
    SMITH, ND
    GRAYHACK, JT
    JOURNAL OF UROLOGY, 1995, 154 (05): : 1802 - 1805
  • [3] Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression
    Levitt J.M.
    Slawin K.M.
    Current Urology Reports, 2007, 8 (4) : 269 - 274
  • [4] TISSUE CONCENTRATIONS OF PROSTATE-SPECIFIC ANTIGEN IN PROSTATIC-CARCINOMA AND BENIGN PROSTATIC HYPERPLASIA
    PRETLOW, TG
    PRETLOW, TP
    YANG, B
    KAETZEL, CS
    DELMORO, CM
    KAMIS, SM
    BODNER, DR
    KURSH, E
    RESNICK, MI
    BRADLEY, EL
    INTERNATIONAL JOURNAL OF CANCER, 1991, 49 (05) : 645 - 649
  • [5] THE ROLE OF PROSTATE-SPECIFIC ANTIGEN IN THE EVALUATION OF BENIGN PROSTATIC HYPERPLASIA
    TCHETGEN, MB
    OESTERLING, JE
    UROLOGIC CLINICS OF NORTH AMERICA, 1995, 22 (02) : 333 - 344
  • [6] AUTOANTIBODIES TO PROSTATE-SPECIFIC ANTIGEN IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
    ZISMAN, A
    ZISMAN, E
    LINDNER, A
    VELIKANOV, S
    SIEGEL, YI
    MOZES, E
    JOURNAL OF UROLOGY, 1995, 154 (03): : 1052 - 1055
  • [7] Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes
    Xu, JF
    Meyers, DA
    Sterling, DA
    Zheng, SQL
    Catalona, WJ
    Cramer, SD
    Bleecker, ER
    Ohar, J
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2002, 11 (07) : 664 - 669
  • [8] IMPACT OF PROSTATE-SPECIFIC ANTIGEN DENSITY IN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CARCINOMA - PRELIMINARY-RESULTS
    AKDAS, A
    DILLIOGLUGIL, O
    CEVIK, I
    ILKER, Y
    EUROPEAN UROLOGY, 1994, 25 (04) : 299 - 303
  • [9] Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia
    Roehrborn, CG
    Boyle, P
    Gould, AL
    Waldstreicher, J
    UROLOGY, 1999, 53 (03) : 581 - 589
  • [10] IMPACT OF PROSTATE-SPECIFIC ANTIGEN DENSITY IN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE - EDITORIAL COMMENT
    OOSTERHOF, GON
    DEBRUYNE, F
    EUROPEAN UROLOGY, 1994, 25 (04) : 304 - 304